Guangzhou Zhongsheng Pharmaceutical (002317.SZ) subsidiary's ZSP1601 tablets included in breakthrough therapy drug program

Zhitong Finance APP News: Zhongsheng Pharmaceutical (002317.SZ) announced that recently, according to the public information released by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, ZSP1601 tablets, a Class 1 innovative drug independently developed by the company's controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., have been included in the CDE's breakthrough therapy drug program. The proposed indication for this drug is metabolic dysfunction-associated steatohepatitis (MASH).